lifestyle.recentlegalnews.com

Author: HANCHORBIO INC.

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

April 24, 2026
HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

March 25, 2026
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

February 13, 2026
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

February 10, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

January 26, 2026
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

December 12, 2025
HanchorBio Presents Preclinical Data on HCB301 at SITC 2025

November 8, 2025
HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology

October 24, 2025